Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence. METHODS: We conducted a 24-week randomized, controlled clinical trial with 166 patients assigned to one of three treatments: standard medical management and either once-weekly or thrice-weekly medication dispensing or enhanced medical management and thrice-weekly medication dispensing. Standard medical management was brief, manual-guided, medically focused counseling; enhanced management was similar, but each session was extended. The primary outcomes were the self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids. RESULTS: The three treatments had similar efficacies with respect to the mean percentage of opioid-negative urine specimens (standard medical management and once-weekly medication dispensing, 44 percent; standard medical management and thrice-weekly medication dispensing, 40 percent; and enhanced medical management and thrice-weekly medication dispensing, 40 percent; P=0.82) and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids. All three treatments were associated with significant reductions from baseline in the frequency of illicit opioid use, but there were no significant differences among the treatments. The proportion of patients remaining in the study at 24 weeks did not differ significantly among the patients receiving standard medical management and once-weekly medication dispensing (48 percent) or thrice-weekly medication dispensing (43 percent) or enhanced medical management and thrice-weekly medication dispensing (39 percent) (P=0.64). Adherence to buprenorphine-naloxone treatment varied; increased adherence was associated with improved treatment outcomes. CONCLUSIONS: Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. Strategies to improve buprenorphine-naloxone adherence are needed. (ClinicalTrials.gov number, NCT00023283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas treatment outcomes did not vary significantly by treatment condition,5 patient satisfaction did (F[2, 139] = 3.16, P = .03).”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
In the citing paper
“This paucity of research is particularly noteworthy given the increasing availability and demonstrated efficacy of office-based buprenorphine/naloxone treatment.5–7”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Crits-Christoph, P. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.493 · Cited by 496
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Carroll, K. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00049-6 · Cited by 386
Research works printed but not linked: 1
- Amato L, 2004, Cochrane Database Syst Rev, 4, CD005031
Cited by
Items 101–200 of 351
Drug Treatment as HIV Prevention: Expanding Treatment Options
Metzger, D. S., & Zhang, Y. (2010) · Current HIV/AIDS Reports · doi:10.1007/s11904-010-0059-z · Cited by 54
“Buprenorphine, a partial agonist with strong affinity to the opiate receptor, expands treatment options in several ways for opiate-dependent individuals [ 17 , 18].”
BackgroundMammen, K., & Bell, J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903213405 · Cited by 49
“The two studies comparing different levels of supervision found no difference in treatment outcomes in these selected participants, supporting the use of models incorporating reduced supervised dosing for some patients [50,51].”
BackgroundMethodResultInfluentialImplementation of buprenorphine in the Veterans Health Administration: results of the first 3 years.
Gordon, A., Trafton, J. A., Saxon, A., Gifford, A., Goodman, F., Calabrese, V. S., McNicholas, L., & Liberto, J. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.03.010 · Cited by 46
The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care
Pryor, J. R., Maalouf, F. I., Krans, E. E., Schumacher, R. E., Cooper, W. O., & Patrick, S. W. (2017) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/archdischild-2015-310045 · Cited by 52
Gunderson, E. W., Wang, X.-Q., Fiellin, D. A., Bryan, B., & LEVIN, F. R. (2010) · Addictive Behaviors · doi:10.1016/j.addbeh.2010.01.001 · Cited by 47
“Brief medical management took place at each visit (Fiellin et al., 2006).”
BackgroundSelf-citationGunderson, E. W., & Fiellin, D. A. (2008) · CNS Drugs · doi:10.2165/00023210-200822020-00002 · Cited by 52
Self-citationBuprenorphine: new treatment of opioid addiction in primary care.
Kahan, M., Srivastava, A., Ordean, A., & Cirone, S. (2011) · PubMed · Cited by 47
Update on the clinical use of buprenorphine: in opioid-related disorders.
Ducharme, S., Fraser, R., & Gill, K. (2012) · Canadian Family Physician · Cited by 53
Attentional bias in opioid users: A systematic review and meta-analysis
MacLean, R. R., Sofuoglu, M., Brede, E., Robinson, C. D., & Waters, A. J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.07.012 · Cited by 47
Identification and Management of Opioid Use Disorder in Primary Care: an Update
Donroe, J. H., Bhatraju, E. P., Tsui, J. I., & Edelman, E. J. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01149-0 · Cited by 51
Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons
Stein, M. D., Herman, D. S., Kettavong, M., Cioe, P. A., Friedmann, P. D., Tellioğlu, T., & Anderson, B. J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.05.014 · Cited by 48
“At each buprenorphine visit, providers offered physician management (PM), a brief (10–15 minutes per session), manual-guided, medically focused advice and brief counseling consistent with the standard of care provided to buprenorphine patients (Fiellin et al., 2006).”
Walley, A. Y., Palmisano, J. N., Sorensen-Alawad, A., Chaisson, C. E., Raj, A., Samet, J. H., & Drainoni, M. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.07.007 · Cited by 47
“Studies of buprenorphine/naloxone treatment integrated into primary care for people with and without HIV have demonstrated reduced opioid use (Fiellin et al., 2006, 2011; Lucas et al., 2010). and a study of HIVinfected patients with opioid dependence, primary care-based buprenorphine treatment…”
Now is the Time to Address Substance Use Disorders in Primary Care
Saitz, R., & Daaleman, T. P. (2017) · The Annals of Family Medicine · doi:10.1370/afm.2111 · Cited by 46
Day, E., & Mitcheson, L. (2017) · Addiction · doi:10.1111/add.13644 · Cited by 52
Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers
Mendoza, S. (2015) · Journal of Addiction Medicine and Therapeutic Science · doi:10.17352/2455-3484.000008 · Cited by 50
“thrice-weekly) are similarly effective [50] and may offer better outcomes for some patients who do not show improvement on standard low doses [51].”
BackgroundShi, J. M., Henry, S. P., Dwy, S. L., Orazietti, S. A., & Carroll, K. M. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1569192 · Cited by 43
“Attrition from buprenorphine treatment carries higher risk of poor outcome, relapse, and death.(5,6) Moreover, although behavioral counseling is required as part of buprenorphine treatment, competent providers of evidence-based behavioral therapies are not always accessible or affordable in office-based settings.”
BackgroundBiondi, B. E., Zheng, X., Frank, C. A., Petrakis, I. L., & Springer, S. A. (2020) · American Journal on Addictions · doi:10.1111/ajad.13051 · Cited by 50
Kennedy, A. J., Wessel, C. B., Levine, R. E., Downer, K., Raymond, M. B., Osakue, D., Hassan, I. F., Merlin, J. S., & Liebschutz, J. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06448-z · Cited by 48
“…AUD, use of methadone or anticonvulsants 6 M Offered weekly, 1-h counseling with addiction psychiatrist Opium dependent only Adjunctive therapy trials Fiellin, 2006† 166 USA, urban, single site, primary care Yale, New Haven, CT SM/1 weekly vs. SM/3 weekly vs. EM/3 weekly 16–24 mg Bup/Na…”
BackgroundMethodInfluentialTetrault, J. M., Moore, B. A., Barry, D. T., O’Connor, P. G., Schottenfeld, R. S., Fiellin, D. A., & Fiellin, L. E. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.07.011 · Cited by 42
Self-citationFinch, J. W., Kamien, J. B., & Amass, L. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31809b5df2 · Cited by 39
Probuphine® (buprenorphine implant): a promising candidate in opioid dependence
Barnwal, P., Das, S., Mondal, S., Ramasamy, A., Maiti, T., & Saha, A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316681984 · Cited by 42
Suzuki, J., Matthews, M. L., Brick, D., Nguyen, M.-T., Jamison, R. N., Ellner, A., Tishler, L. W., & Weiss, R. D. (2014) · Journal of Opioid Management · doi:10.5055/jom.2014.0204 · Cited by 40
Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy
Bentzley, B. S., Barth, K. S., Back, S. E., Aronson, G., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.04.002 · Cited by 38
“…medication management appointments, or reducing or eliminating the need for counseling in select patients, as counseling has not been shown to improve outcomes beyond BMT alone (Amato, Minozzi, Davoli, & Vecchi, 2011; Downey, Helmus, & Schuster, 2000; Fiellin et al., 2006, 2013; Ling et al., 2013).”
Meara, E. R., Golberstein, E., Zaha, R. L., Greenfield, S. F., Beardslee, W. R., & Busch, S. H. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3972 · Cited by 44
Havens, J. R., WALSH, S. L., Korthuis, P. T., & Fiellin, D. A. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0402-3 · Cited by 39
Self-citationHjelmström, P., Nordbeck, E. B., & Tiberg, F. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1706552 · Cited by 42
Kamien, J. B., Branstetter, S. A., & Amass, L. (2008) · Heroin addiction and related clinical problems · Cited by 50
Primary care patient characteristics associated with completion of 6-month buprenorphine treatment
Neumann, A. M., Blondell, R. D., Azadfard, M., Nathan, G., & Homish, G. G. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.07.007 · Cited by 37
Buprenorphine/Naloxone for opioid dependence: clinical practice guideline.
Handford, C. D., Kahan, M., Srivastava, A., Cirone, S., & Palda, V. A. (2011) · Cited by 51
Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
Fraser, R., Mauger, S., & Gill, K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39692 · Cited by 47
Copenhaver, M. M., Bruce, R. D., & Altice, F. L. (2007) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990701522674 · Cited by 38
“Other studies have reported a 48% retention rate among higher functioning opioiddependent patients treated with buprenorphine for 24 weeks in an office-based setting (11).”
BackgroundChawarski, M. C., Mazlan, M., & Schottenfeld, R. S. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.008 · Cited by 38
Self-citationWen, H., Hockenberry, J. M., & Pollack, H. A. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2943 · Cited by 39
Association Between Medicaid Expansion and Rates of Opioid-Related Hospital Use
Wen, H., Soni, A., Hollingsworth, A. J., Freedman, S. M., Benitez, J. A., Simon, K. I., & Saloner, B. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0473 · Cited by 37
“18 All models were weighted by state population30 and included time-varying control variables that adjusted for statelevel health care supply, general economic conditions, and concurrent policies, including (1) per capita number of hospital beds, (2) poverty rate, (3) unemployment rate, (4) establishment and (5) compr…”
BackgroundTreatment of Adolescent Opioid Dependence: No Quick Fix
Fiellin, D. A. (2008) · JAMA · doi:10.1001/jama.2008.567 · Cited by 40
Self-citationHeimer, R., McNeil, R., & Vlahov, D. (2020) · Journal of Urban Health · doi:10.1007/s11524-020-00465-3 · Cited by 34
Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence
Chawarski, M. C., Fiellin, D. A., O’Connor, P. G., Bernard, M., & Schottenfeld, R. S. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.03.004 · Cited by 34
“A subset of 63 patients enrolled in a randomized clinical trial of the efficacy of buprenorphine maintenance (Fiellin et al., 2006) received PharmChek sweat patches in addition to weekly urine toxicology screens and weekly self-reports.”
BackgroundSelf-citationPrice, C. J., Merrill, J. O., McCarty, R. L., Pike, K. C., & Tsui, J. I. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.05.013 · Cited by 33
“, 2017), and when not taking medications patients frequently relapse to illicit opiate use (Fiellin et al., 2006).”
BackgroundOutpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl
Suen, L. W., Chiang, A. Y., Jones, B. L. H., Soran, C. S., Geier, M., Snyder, H. R., Neuhaus, J. M., Myers, J. J., Knight, K. R., Bazazi, A. R., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.56253 · Cited by 34
Stein, M., Herman, D. S., Moitra, E., Hecht, J., Lopez, R., Anderson, B., & Brown, R. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.11.007 · Cited by 36
“At each visit beginning at induction, brief physician management (PM) counseling was provided by either of the two study clinicians (Fiellin et al., 2006, 2002).”
MethodThe Andalusian trial on heroin‐assisted treatment: A 2 year follow‐up
Oviedo‐Joekes, E., March, J. C., ROMERO, M., & Perea‐Milla, E. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00100.x · Cited by 33
Golan, O. K., Totaram, R., Perry, E. W., Fortson, K., Rivera-Atilano, R., Entress, R. M., Golan, M., Andraka‐Christou, B., Whitaker, D. J., & Pigott, T. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109445 · Cited by 35
Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility
Sigmon, S. C., Meyer, A. C., Hruska, B. J., Ochalek, T. A., Rose, G. L., Badger, G. J., Brooklyn, J. R., Heil, S. H., Higgins, S. T., Moore, B. A., et al. (2015) · Addictive Behaviors · doi:10.1016/j.addbeh.2015.07.030 · Cited by 32
“Similar to prior studies (Fiellin et al., 2006), buprenorphine adherence was evaluated using a review of nurses' notes, random call-back data and Med-O-Wheel monitoring.”
BackgroundMethodSelf-citationSchottenfeld, R. S., Chawarski, M. C., Cubells, J. F., George, T. P., Lappalainen, J., & Kosten, T. R. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.007 · Cited by 31
Self-citationMeade, C. S., Weiss, R. D., Fitzmaurice, G. M., Poole, S. A., Subramaniam, G., Patkar, A. A., Connery, H. S., & WOODY, G. E. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181d916db · Cited by 31
Donroe, J. H., Holt, S. R., O’Connor, P. G., Sukumar, N., & Tetrault, J. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.07.040 · Cited by 31
Self-citationSpotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†
Orman, J. S., & Keating, G. M. (2009) · CNS Drugs · doi:10.2165/11203740-000000000-00000 · Cited by 31
The Impact of Cocaine Use on Outcomes in HIV-Infected Patients Receiving Buprenorphine/Naloxone
Sullivan, L. E., Botsko, M., Cunningham, C. O., O’Connor, P. G., Hersh, D., Mitty, J. A., Lum, P. J., Schottenfeld, R. S., & Fiellin, D. A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097576 · Cited by 30
Self-citationMcHugh, R. K., Votaw, V. R., Barlow, D. H., Fitzmaurice, G. M., Greenfield, S. F., & Weiss, R. D. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.006 · Cited by 33
“Although significant progress has been made developing [70-73] and expanding access [74-76] to medication-assisted treatments for opioid use disorder, approximately 30-50% of patients discontinue treatment prematurely [70, 77-80] and 40-80% continue to use opioids during treatment [81].”
The End of the X-waiver: Excitement, Apprehension, and Opportunity
LeFevre, N. M., Louis, J. S., Worringer, E., Younkin, M., Stahl, N. E., & Sorcinelli, M. D. (2023) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2023.230048r1 · Cited by 29
“17,18 Furthermore, surveyed physicians report a lack of expertise and comfort related to addiction medicine broadly and buprenorphine speci fi cally, 19 likely related to the inadequacy of medical school and residency education around addiction medicine, which has likewise been well-documented…”
BackgroundHui, D. S. C., Weinstein, Z., Cheng, D. M., Quinn, E. K., Kim, H. W., LaBelle, C. T., & Samet, J. H. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.05.010 · Cited by 29
“(Amass et al., 2012; Cunningham et al., 2013; Fiellin et al., 2006; Hser et al., 2014; Mattick et al., 2003; Schuman-Olivier et al., 2014; Sohler et al., 2010; Stein et al., 2005) These results are encouraging when considering the evidence that patients leaving OUD treatment experience high rates of return to opioid u…”
BackgroundResultInfluentialSokol, R. G., Albanese, C., Chaponis, D. M., Early, J., Maxted, G., Morrill, D., Poirier, G., Puopolo, F., & Schuman‐Olivier, Z. (2017) · Substance Abuse · doi:10.1080/08897077.2017.1356792 · Cited by 31
“Previous studies reporting the benefits of B/N delivery compared B/N being delivered with and without individual therapy and found no differences in patient outcomes.(15,16) However, these studies did not evaluate the benefits of group delivery of therapeutic support and focused on quantitative outcomes.”
Godersky, M. E., Klein, J. W., Merrill, J. O., Blalock, K. L., Saxon, A. J., Samet, J. H., & Tsui, J. I. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000608 · Cited by 28
“One study utilizing computerized medication bottle caps to monitor buprenorphine administration in an office-based setting demonstrated 71% adherence (Fiellin et al., 2006), leaving room for improvement.”
BackgroundWeintraub, E., Greenblatt, A. D., Chang, J. W., Welsh, C., Berthiaume, A. P., Goodwin, S. R., Arnold, R., Himelhoch, S. S., Bennett, M. E., & Belcher, A. M. (2021) · Heroin addiction and related clinical problems · Cited by 41
Moore, B. A., Barry, D. T., Sullivan, L. E., O’Connor, P. G., Cutter, C. J., Schottenfeld, R. S., & Fiellin, D. A. (2012) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182596492 · Cited by 32
“Notably, in one study, patients with higher levels of documented medication adherence had improved buprenorphine treatment outcomes (Fiellin et al., 2006).”
BackgroundMethodResultInfluentialSelf-citationNon-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review.
Tetrault, J. M., & Butner, J. L. (2015) · PubMed Central · Cited by 27
Puffer, E. S., Skalski, L. M., & Meade, C. S. (2010) · Journal of Religion and Health · doi:10.1007/s10943-010-9418-8 · Cited by 39
“such as buprenorphine are often used to ease withdrawal and reduce opioid use (Fiellin et al. 2006; Jones 2004; Ling et al. 2005; Woody et al. 2008).”
Pilarinos, A., Barker, B., Nosova, E., Milloy, M., Hayashi, K., Wood, E., Kerr, T., & DeBeck, K. (2019) · Addiction · doi:10.1111/add.14769 · Cited by 31
Effect of Incarceration History on Outcomes of Primary Care Office-based Buprenorphine/Naloxone
Wang, E. A., Moore, B. A., Sullivan, L. E., & Fiellin, D. A. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1306-0 · Cited by 25
“Abstinence in the 2 weeks of induction, %(N) 56 (64) 44 (23) 0.15 0.32 Treatment completion, % (N) 46 (52) 38 ( 20 ) 0.39 0.28 Retention, weeks, mean (SD) 17.6 (7.7) 17.9 (7.0) 0.79 0.42 Percent opioid-negative urines with missing counted as positive, mean (SD) 42 (34.3) 43 (30.5) 0.85 0.38 Continuous opioid abstinenc…”
InfluentialSelf-citationTrauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder
Meshberg‐Cohen, S., Black, A. C., DeViva, J. C., Petrakis, I. L., & Rosen, M. I. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.010 · Cited by 27
Buprenorphine treatment for opioid use disorder: recent progress
Parida, S., Carroll, K. M., Petrakis, I. L., & Sofuoglu, M. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635454 · Cited by 23
Wyse, J. J. B., Morasco, B. J., Dougherty, J., Edwards, B., Kansagara, D. L., Gordon, A. J., Korthuis, P. T., Tuepker, A., Lindner, S., Mackey, K., et al. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108923 · Cited by 27
Korthuis, P. T., Cook, R., Lum, P. J., Waddell, E. N., Tookes, H., Vergara‐Rodriguez, P., Kunkel, L. E., Lucas, G. M., Rodriguez, A. E., Bielavitz, S., et al. (2022) · Addiction · doi:10.1111/add.15836 · Cited by 26
Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial
Edelman, E. J., Maisto, S. A., Hansen, N. B., Cutter, C. J., Dziura, J., Deng, Y., Fiellin, L. E., O’Connor, P. G., Bedimo, R., Gibert, C. L., et al. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.08.007 · Cited by 25
“Step 3 included Addiction Psychiatrist-delivered Addiction Physician Management (APM) with an emphasis on consideration of medications to decrease alcohol use with medical management, consistent with the approach used to provide buprenorphine for treatment of opioid use disorder in HIV treatment settings (Fiellin et a…”
MethodSelf-citationSchramm, Z. A., Leroux, B. G., Radick, A. C., Ventura, A. S., Klein, J. W., Samet, J. H., Saxon, A. J., Kim, T. W., & Tsui, J. I. (2020) · Addiction Science & Clinical Practice · doi:10.1186/s13722-020-00203-9 · Cited by 23
Tsui, J. I., Leroux, B. G., Radick, A. C., Schramm, Z. A., Blalock, K. L., LaBelle, C. T., Heerema, M. R., Klein, J. W., Merrill, J. O., Saxon, A. J., et al. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108917 · Cited by 24
Suzuki, J., Zinser, J., Klaiber, B., Hannon, M., Grassi, H., Spinosa, M., Ramirez, A., Issa, M., & Chin Feman, S. P. (2015) · Substance Abuse · doi:10.1080/08897077.2014.998400 · Cited by 23
“In a study of 166 opioid-dependent subjects randomized to receive buprenorphine and various intensities of concurrent counseling, between 39% and 48% remained in treatment at 6 months, with significant reduction in opioid use as evidenced by self-report and urine toxicology.(8) In another randomized trial comparing bu…”
MethodResultFriedmann, P. D., & Suzuki, J. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0092-y · Cited by 24
“Clinical outcomes for OUD are best while medication is continued, then the decay is precipitous once the pharmacotherapy is stopped, regardless of whether the taper is short, long or in-between [7, 13–16], and whether or not accompanied by intensive counseling and services [17, 18].”
BackgroundNew Approaches in Drug Dependence: Opioids
Mielau, J., Vogel, M., Gutwinski, S., & Mick, I. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00373-9 · Cited by 29
“Among 166 patients receiving BNX in primary care for opioid dependence, the efficacy of brief weekly counseling and onceweekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing [50].”
BackgroundEvren, C., Karabulut, V., Can, Y., Bozkurt, M., Umut, G., & Evren, B. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20140310072258 · Cited by 24
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.
Nalven, T., Spillane, N. S., Schick, M. R., & Weyandt, L. L. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000510 · Cited by 22
Office-Based Addiction Treatment in Primary Care
Edelman, E. J., Oldfield, B. J., & Tetrault, J. M. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.007 · Cited by 22
Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment
Baldassarri, S. R., Fiellin, D. A., Savage, M. E., Madden, L. M., Beitel, M., Dhingra, L. K., Fucito, L. M., Camenga, D. R., Bollampally, P., & Barry, D. T. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.12.012 · Cited by 21
Self-citationIntegrating addiction medicine into rural primary care: Strategies and initial outcomes.
Logan, D. E., Lavoie, A. M., Zwick, W. R., Kunz, K., Bumgardner, M. A., & Molina, Y. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000410 · Cited by 22
Saunders, E. C., Moore, S. K., Walsh, O., Metcalf, S. A., Budney, A. J., Cavazos‐Rehg, P. A., Scherer, E. A., & Marsch, L. A. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00213-1 · Cited by 21
Zhu, Y., Coyle, D. T., Mohamoud, M., Zhou, E. H., Eworuke, E., Dormitzer, C. M., & Staffa, J. A. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.019 · Cited by 21
“MAT is a mainstay of treatment for OUD and has been shown to be effective in reducing opioid use and opioid craving among affected individuals (Connery, 2015; Fiellin et al., 2006; Fudala et al., 2003; Volkow et al., 2014).”
BackgroundDaulouède, J., Caer, Y., Galland, P., Villéger, P., Brunelle, E., Bachellier, J., Piquet, J.-M., Harbonnier, J., Léglise, Y., & Courty, P. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.07.002 · Cited by 20
“Furthermore, treatment compliance with buprenorphine/naloxone, as with other opioid dependence treatments, has been associated with improved rates of opioid abstinence (Fiellin et al., 2006).”
BackgroundSocias, M. E., Wood, E., Dong, H., Brar, R., Bach, P., Murphy, S. M., & Fairbairn, N. S. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.105993 · Cited by 22
“Typically, these visits include education on OUD and MOUD, monitoring of efficacy, side effects, and adherence to the assigned MOUD, as well as potential dose adjustments, review of use of opioids and other substances, as well as referrals to other health and social services, as needed and appropriate [36].”
BackgroundPsychotherapies in opioid use disorder: toward a step-care model
Durpoix, A., Rolling, J., Coutelle, R., & Lalanne, L. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02720-8 · Cited by 22
“When Fiellin et al. (2006) compared the group of patients who benefit from this intervention with other groups who benefit from a more intense intervention, they found no superiority of the latter group compared with the former.”
BackgroundResultWilliams, A. R., Krawczyk, N., Hu, M., Harpel, L., Aydinoglo, N., Cerdá, M., Rotrosen, J., & Nunes, E. V. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100636 · Cited by 30
Office-Based Opioid Dependence Treatment
Colson, J. D., Helm, S., & Silverman, S. M. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es231 · Cited by 19
Buprenorphine 101: Treating Opioid Dependence with Buprenorphine in an Office-Based Setting
Torrington, M., Domier, C. P., Hillhouse, M. P., & Ling, W. W. (2007) · Journal of Addictive Diseases · doi:10.1300/j069v26n03_10 · Cited by 21
Marcus, R., Bojko, M. J., Mazhnaya, A., Makarenko, I., Filippovych, S., Дворяк, С., Altice, F. L., & Springer, S. A. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.01.003 · Cited by 22
“Their experience with daily treatment with MMT or BMT provided continuous contact and support from a doctor, nurse, or social worker.”
BackgroundInfluentialApproaches to Behavioral Health Integration at High Performing Primary Care Practices
Blasi, P. R., Cromp, D., McDonald, S., Hsu, C. W., Coleman, K., Flinter, M., & Wagner, E. H. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.05.170468 · Cited by 19
“Primary care practices are the front lines for identifying and responding to a wide range of patient needs, and BH integration can help practices address patients’ behavioral health,(8) physical health,(13) chronic pain,(52) substance use,(18,19) and opioid dependency.(18,53,54) As the US health care system works towa…”
BackgroundInterim versus standard methadone treatment: A benefit–cost analysis
Schwartz, R. P., Alexandre, P. K., Kelly, S. M., O’Grady, K. E., Gryczynski, J., & Jaffe, J. H. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.10.003 · Cited by 21
Suboxone Misuse Along the Opiate Maintenance Treatment Pathway
Furst, R. T. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759860 · Cited by 21
Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program
Baxter, J. D., Clark, R. E., Samnaliev, M., Aweh, G. N., & O’Connell, E. (2015) · Substance Abuse · doi:10.1080/08897077.2014.991469 · Cited by 21
Lowenstein, M., Abrams, M. P., Crowe, M., Shimamoto, K., Mazzella, S., Botcheos, D., Bertocchi, J., Westfahl, S., Chertok, J., Garcia, K. P., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109915 · Cited by 23
Yarbrough, C. R., Abraham, A. J., & Adams, G. B. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201900150 · Cited by 19
Presnall, N. J., Wolf, D. A. P. S., Brown, D. S., Beeler‐Stinn, S., & Grucza, R. A. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.06.010 · Cited by 17
Edelman, E. J., Maisto, S. A., Hansen, N. B., Cutter, C. J., Dziura, J. D., Deng, Y., Fiellin, L. E., O’Connor, P. G., Bedimo, R. G., Gibert, C. L., et al. (2020) · Addiction Science & Clinical Practice · doi:10.1186/s13722-020-00200-y · Cited by 17
Self-citationBenville, J. R., Compton, P. A., Giordano, N. A., & Cheatle, M. D. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108619 · Cited by 20
Martínez-Raga, J., Saiz, F. G., Pascual, C., Casado, M. Á., & Torres, F. J. S. (2009) · European Addiction Research · doi:10.1159/000259614 · Cited by 16
“Despite availability, increasingly easy access, popularity, and the well-documented effectiveness of MM programs, many patients fail to improve and are unable to achieve and to maintain abstinence while on methadone. In addition, the regulated environment in which methadone is generally dispensed (often at clinics ser…”
BackgroundBrown, R. A., Bloom, E. L., Hecht, J., Moitra, E., Herman, D. S., & Stein, M. D. (2014) · Behavior Modification · doi:10.1177/0145445514538279 · Cited by 20
“This level of physician counseling is consistent with the standard of care provided to buprenorphine patients and has been used in other office-based buprenorphine trials (Fiellin et al., 2006).”
ResultMutlu, C., Demirci, A. Ç., Yalçın, Ö., Kılıçoğlu, A. G., Topal, M., & Karaçetin, G. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.04.002 · Cited by 19
“Adult studies examining long term treatmentwith BUP/NAL revealed a 39 to 63% program retention rate at 6 months, and 53% at 1 year (Fiellin et al., 2006; Armstrong et al., 2010; Fiellin et al., 2008).”
BackgroundInfluentialTreatment Options for Opioid Use Disorders: A Review of the Relevant Literature
Mumba, M. N., Findlay, L. J., & Snow, D. E. (2018) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000241 · Cited by 19
The medical management of opioid dependence in HIV primary care settings
Lum, P. J., & Tulsky, J. P. (2006) · Current HIV/AIDS Reports · doi:10.1007/s11904-006-0016-z · Cited by 16
“For the well-maintained patient, monthly assessments and prescription refills are feasible and acceptable, though the optimal dose and frequency of on-site counseling is still unknown [ 85 ].”
BackgroundYue, J.-L., Yuan, K., Bao, Y., Meng, S., Shi, L., Fang, Q., Guo, X.-J., Cao, L., Sun, Y., Lu, T., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104283 · Cited by 18
Spelman, J. F., Edens, E. L., Maya, S., Moore, B. A., Boggs, A. M., MacLean, R. R., Ackland, P. E., Becker, W. C., Lynch, D., Garcia-Vassallo, M., et al. (2021) · Federal Practitioner · doi:10.12788/fp.0186 · Cited by 15
Rieckmann, T. R., Abraham, A. J., Kovas, A. E., McFarland, B. H., & Roman, P. M. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.01.016 · Cited by 16
“…clinical trials of buprenorphine (Subutex®) and buprenorphine/naloxone (Suboxone®) indicate that it is more effective than placebos and equally effective as methadone in reducing opioid use (Donaher & Welsh, 2006; Johnson et al., 2000; Comer et al., 2005; Fiellin et al., 2006; Kahan et al., 2011).”
Background
Metadata
- Authors
- Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S.
- Affiliations
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-27
- Volume
- 355
- Issue
- 4
- Pages
- 365-374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964032526
- Cited by
- 351
- References
- 30
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 17 · 2023: 14 · 2022: 13 · 2021: 28 · 2020: 18 · 2019: 24 · 2018: 22 · 2017: 19 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 15
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA000445, K23 DA15144, R01DA009803, K12 DA00167, K23DA015144, K12DA000167)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine/naloxone, medication-assisted treatment, counseling, primary care, medication adherence, opioid abstinence, urine drug testing, treatment retention
- MeSH terms
- Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Humans, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.